Ghana to India Pharmaceutical Import

The pharmaceutical trade corridor between Ghana and India has remained relatively underdeveloped from 2022 to 2026. Between 2022 and 2026, India imported a total of $10 worth of finished pharmaceutical formulations from Ghana, comprising a single shipment of plasma. This limited trade volume indicates minimal engagement in this sector during the specified period.

Ghana's contribution to India's pharmaceutical imports is negligible, accounting for only $10 over the 2022-2026 period. The sole product imported was plasma, highlighting Ghana's minimal presence in India's pharmaceutical import landscape.

Between 2024 and 2026, there were no significant policy changes, trade agreements, or regulatory harmonization efforts by the Central Drugs Standard Control Organisation (CDSCO) that impacted the pharmaceutical trade between Ghana and India. The lack of substantial trade activity suggests limited bilateral engagement in this sector during this timeframe.

For Ghanaian companies aiming to export pharmaceutical products to India, obtaining registration with the CDSCO is mandatory. The process involves several key steps:

1. Online Application: Applicants must visit the CDSCO SUGAM portal and create an account by providing necessary details such as applicant type, username, password, and contact information.

2. Form Submission: After account activation, applicants need to submit the appropriate form (e.g., Form 40 for importers) along with required documents, including identity proof, address proof, and an undertaking as specified by CDSCO.

3. Verification and Approval: Once submitted, the application undergoes verification by CDSCO officials. This may involve site inspections and consultations with subject-matter experts to assess the safety and efficacy of the products.

4. License Issuance: Upon successful evaluation, CDSCO grants the necessary licenses, authorizing the import and distribution of the pharmaceutical products in India.

The entire process can take several months, depending on the complexity of the application and the regulatory requirements.

India requires that pharmaceutical products imported from Ghana adhere to Good Manufacturing Practices (GMP) standards. Manufacturing sites in Ghana must be WHO-GMP certified to ensure compliance with international quality standards. CDSCO may conduct inspections to verify adherence to these standards before granting import licenses.

To import pharmaceutical products into India, Ghanaian companies must provide several key documents:

• Import License (Form 10): This license authorizes the importation of pharmaceutical products into India.

• Registration Certificate: Issued by CDSCO, this certificate confirms that the imported products are approved for sale and distribution in India.

• No Objection Certificate (NOC): This document, typically obtained from the exporting country's regulatory authority, certifies that the products are free from any legal encumbrances.

• Test License: Required for conducting quality control tests on imported pharmaceutical products to ensure they meet Indian standards.

• Customs Procedures: Compliance with Indian customs regulations is essential, including proper documentation and payment of applicable duties and taxes.

The pharmaceutical imports from Ghana to India are limited, with plasma being the only product imported during the 2022-2026 period. This indicates a lack of diversity in the types of pharmaceutical products traded between the two countries.

Given the minimal trade volume, there is no significant importation of innovator drugs, novel formulations, or advanced therapies from Ghana to India. The trade is restricted to a single product category, plasma, without diversification into other pharmaceutical specialties.

The negligible import demand from Ghana to India can be attributed to several factors:

• Patent Protection: India's robust patent laws may limit the importation of patented drugs from Ghana.

• Technology Gaps: India's advanced pharmaceutical manufacturing capabilities reduce the need for imports from Ghana.

• Quality Requirements: Stringent quality standards in India necessitate that imported products meet high criteria, which may not be consistently met by Ghanaian manufacturers.

• Disease Burden: The prevalence of diseases in India may not align with the therapeutic areas of Ghanaian pharmaceutical products, leading to limited demand.

India's import tariff structure for pharmaceutical formulations includes:

• Most Favored Nation (MFN) Tariff Rates: Standardized rates applied to imports from all WTO member countries.

• Basic Customs Duty: A duty imposed on imported goods, varying based on product classification.

• Integrated Goods and Services Tax (IGST): A tax levied on imported goods, applicable at the time of importation.

• Health Cess: An additional levy on imported pharmaceutical products, intended to fund health initiatives.

These tariffs and taxes collectively impact the pricing and competitiveness of imported pharmaceutical products in the Indian market.

As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Ghana concerning pharmaceutical imports. India's participation in regional agreements like the Regional Comprehensive Economic Partnership (RCEP) does not currently include Ghana, limiting the scope for preferential trade terms in the pharmaceutical sector.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and restricts the patentability of new forms of known substances unless they demonstrate enhanced efficacy. This provision may affect the importation of certain pharmaceutical products from Ghana. Additionally, the National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines in India, which can influence the pricing strategies of imported drugs.

The limited pharmaceutical trade between Ghana and India results in minimal shipping activity. For the single shipment of plasma, the most likely route would involve sea freight from Ghana's ports to major Indian ports, such as Mumbai or Chennai. Transit times would vary depending on the specific ports and shipping schedules but are generally in the range of 20-30 days.

Ghana's primary export ports include Tema and Takoradi, which handle a significant portion of the country's maritime trade. In India, major import ports include Mumbai, Chennai, and Kolkata, equipped with facilities to handle pharmaceutical imports. However, the minimal trade volume between Ghana and India suggests limited utilization of these ports for such transactions.

For pharmaceutical imports, Indian customs procedures require compliance with CDSCO regulations, including product registration and quality testing. Cold chain management is critical for temperature-sensitive products like plasma. Importers must ensure that the entire logistics chain adheres to Good Distribution Practices (GDP) to maintain product integrity upon arrival in India.

Despite being a major pharmaceutical manufacturer, India imports certain specialized products not produced domestically. However, the negligible import volume from Ghana indicates that India does not currently rely on Ghana for these specialized pharmaceutical products.

The limited trade suggests that Ghanaian pharmaceutical companies have minimal presence in the Indian market. There are no significant strategies, local partnerships, or contract manufacturing arrangements reported between Ghanaian companies and Indian entities in the pharmaceutical sector.

India's "Atmanirbhar Bharat" initiative and the Production Linked Incentive (PLI) scheme aim to boost domestic manufacturing and reduce import dependency. These policies are likely to further diminish the need for pharmaceutical imports from countries like Ghana, potentially leading to a decline or substitution of such imports in the future.

India's pharmaceutical imports are predominantly sourced from countries like the United States, European Union nations, China, Switzerland, and Japan. Ghana's share in this import landscape is negligible, with the single shipment of plasma in 2022-2026 representing a minuscule fraction compared to imports from these other countries.

While Ghana may offer competitive pricing and quality in certain pharmaceutical products, the lack of significant trade suggests that Indian buyers do not perceive substantial advantages in sourcing from Ghana. Factors such as established trade relationships, regulatory compliance, and product availability from other countries likely outweigh any potential benefits from Ghanaian imports.

Indian pharmaceutical manufacturers are continually developing alternatives to imported products, including biosimil